Erectile dysfunction: Three rare cases of <i>Qsymia</i> side effect

Introduction: Sold under the brand name of Qsymia, the combination of phentermine and topiramate is a common medication used as an adjunct therapy for weight loss. Despite previous animal studies showing adverse effect to male rate infertility, sexual dysfunction including erectile dysfunction (ED) was not reported as an adverse effect for patient with obesity taking Qsymia. Case Report: We presented three cases of patients with obesity who reported ED as an adverse effect of Qsymia with two cases demonstrating reversibility with either discontinuation of the medication or supplementation with Sildenafil. All the patients have comorbidities for ED and two patients have predisposition to ED. We discussed the potential mechanisms of action for the different components of Qsymia causing ED in the three cases by reviewing previous literatures. Conclusion: Given the reversibility of ED and sufficient therapeutic effects, Qsymia should remain as the adjunct therapy for obesity along with diet modification and physical activities.

Authors

Institutions

Publication Details

Journal
Journal of Case Reports and Images in Medicine
Published
2025-12-03
DOI
https://doi.org/10.5348/100082z09hy2025cs
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Erectile dysfunction: Three rare cases of Qsymia side effect

Pratima Sood, Haitong Yu
Journal of Case Reports and Images in Medicine
Pharmacology and Obesity Treatment
article

Erectile dysfunction: Three rare cases of Qsymia side effect

Pratima Sood, Haitong Yu
article en

Abstract

Introduction: Sold under the brand name of Qsymia, the combination of phentermine and topiramate is a common medication used as an adjunct therapy for weight loss. Despite previous animal studies showing adverse effect to male rate infertility, sexual dysfunction including erectile dysfunction (ED) was not reported as an adverse effect for patient with obesity taking Qsymia. Case Report: We presented three cases of patients with obesity who reported ED as an adverse effect of Qsymia with two cases demonstrating reversibility with either discontinuation of the medication or supplementation with Sildenafil. All the patients have comorbidities for ED and two patients have predisposition to ED. We discussed the potential mechanisms of action for the different components of Qsymia causing ED in the three cases by reviewing previous literatures. Conclusion: Given the reversibility of ED and sufficient therapeutic effects, Qsymia should remain as the adjunct therapy for obesity along with diet modification and physical activities.

Journal of Case Reports and Images in MedicineVol. 10(2)
Louis Stokes Cleveland VA Medical Center (US), University School (US), Case Western Reserve University (US)
Openalex Percentile: Top 59%
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Erectile dysfunction: Three rare cases of <i>Qsymia</i> side effect — Pratima Sood, Haitong Yu · Journal of Case Reports and Images in Medicine (2025) | TGRS Research Map | TGRS